Compare Crispr Therapeutics AG (CRSP) vs iShares MSCI Indonesia ETF (EIDO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs iShares MSCI Indonesia ETF — how do they compare? Crispr Therapeutics AG trades at $53.95 (market cap $5.17B), while iShares MSCI Indonesia ETF trades at $12.47. Which is the better fit depends on your goals.
| CRSP | EIDO | |
|---|---|---|
Market Cap | $5.17B | — |
Sector | Health | — |
52-Week High | $76.78 | $19.22 |
52-Week Low | $44.34 | $10.80 |
Enterprise Value | $3.59B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.52, up 3.64% in the last session, with a bullish technical outlook from moving averages but overbought RSI signals. The company reported a Q2 2026 loss of $0.94 per share, beating estimates, while revenue growth is driven by Casgevy sales. Analyst consensus is a Buy with a $76 price target, reflecting optimism for pipeline catalysts.
The outlook is supported by strong product sales and clinical progress, but significant risks include persistent negative margins, high cash burn, and reliance on pipeline success. Investors face a high-risk, high-reward scenario with the stock trading near resistance levels amid volatile earnings history.
EIDO, the iShares MSCI Indonesia ETF, trades at $12.91, up 2.38% today, with a bullish technical signal from moving averages but neutral oscillators. The stock shows support and resistance clustered around $13. Recent news highlights Indonesia's economic initiatives, including AI integration in government programs and reforestation plans, while facing challenges from foreign capital outflows and central bank rate hikes to support the rupiah.
The outlook for EIDO is mixed, with low valuation offering potential upside, but weak price action and high financial sector exposure limit gains. Risks include geopolitical volatility and dependence on commodity markets, though government reforms could boost long-term growth. Investors should weigh bargain valuations against macroeconomic headwinds for balanced exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About iShares MSCI Indonesia ETF
The fund generally will invest at least 80% of its assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The index is a free float-adjusted market capitalization-weighted index that is designed to measure the performance of the large-, mid- and small-capitalization segments of the equity market in Indonesia. The fund is non-diversified.
Read more on EIDO →
